Search retatrutide benefits and you get a list built from four different drugs. Retatrutide's own human record is a single published trial: 338 adults, 48 weeks, reported in 2023.
The short answer. The only benefit measured in a retatrutide trial is body-weight reduction, plus glycemic secondary endpoints, in 338 adults over 48 weeks.
- The headline figures are 24.2% at 12 mg against 2.1% on placebo, with 83% of that arm losing 15% or more.
- Claims about energy expenditure from the glucagon arm are mechanistic. No published human study splits the 24.2% between the three receptors.
- Cardiovascular, kidney and sleep-apnea benefits come from semaglutide and tirzepatide outcome trials. Retatrutide has none completed.
Retatrutide has one published human trial. It ran 48 weeks in 338 adults. The 12 mg arm lost 24.2% of body weight. Placebo lost 2.1%. Most other benefits you read belong to other drugs. No heart or kidney outcome trial has finished.
Which retatrutide benefits are measured, and which are borrowed
Retatrutide is one molecule that binds three receptors: GIP, GLP-1 and glucagon. Marketing pages treat each receptor as a separate promise. The published evidence does not split that way.
Here is every common claim, traced to where the number actually came from.
| Claim | Where the evidence comes from | Retatrutide human data? |
|---|---|---|
| Large body-weight reduction | Phase 2 trial, Jastreboff et al., NEJM 2023 | Yes — one trial, 338 adults |
| Reduced appetite and food intake | The GLP-1 receptor arm, shared with semaglutide and tirzepatide | Not reported as a separated endpoint |
| Higher energy expenditure / "extra fat burn" | The glucagon receptor arm; preclinical and mechanistic rationale | No published human measurement |
| Better blood sugar | Glycemic secondary endpoints in the same Phase 2 trial | Yes, as secondary endpoints |
| Fewer heart attacks and strokes | Cardiovascular outcome trials of semaglutide and tirzepatide | None completed |
| Sleep apnea, knee pain, kidney protection | Tirzepatide and semaglutide programs | None |
Only two rows of that table describe something a retatrutide trial measured. The rest are inferences from a drug class. They may turn out to hold. As of now, nobody has shown it for this molecule.
The weight-loss number, and exactly where it came from
This is the measured benefit. Jastreboff and colleagues randomized 338 adults with obesity to retatrutide at 1, 4, 8 or 12 mg once weekly, or placebo, for 48 weeks. Entry required a BMI of 30, or 27 with a weight-related illness.
At the top dose, mean body weight fell 24.2%. Placebo fell 2.1%. In that top arm, 83% of participants lost 15% or more of their starting weight.
In persons with obesity, 48 weeks of treatment with retatrutide resulted in substantial reductions in body weight.
Jastreboff et al., New England Journal of Medicine, 2023Three things about that sentence are worth holding onto:
- It is Phase 2. A dose-finding study, not a confirmatory one. Phase 3 TRIUMPH is what tests whether the effect holds at scale.
- Weight is a scale reading, not an outcome. It is not the same claim as fewer heart attacks or longer life.
- The trial had not plateaued. The dose-response ran almost straight up to 12 mg, which is a finding about the dose range, not a promise about the ceiling.
We take the design apart in the Phase 2 trial deep dive, and the full arm-by-arm spread sits on retatrutide before and after.
Three receptors in one vial: what each part is credited with
The interesting design question is what the glucagon arm adds. GIP and GLP-1 agonism is what tirzepatide already does. Glucagon receptor agonism is the new ingredient.
The rationale is that glucagon signaling raises energy expenditure and mobilizes liver fat, on top of the appetite suppression the GLP-1 arm provides. Melson and colleagues place retatrutide in this triple-agonist branch of the obesity pipeline in their 2024 review for the International Journal of Obesity.
Here is the limitation almost every benefits page leaves out: the Phase 2 trial gave one molecule that hits all three receptors at once. No published human study attributes a share of the 24.2% to any single receptor. The mechanism is a hypothesis about why the number is large, not a measurement of its parts.
So a claim like "the glucagon arm burns more calories at rest" is a mechanistic story. It is not a reported human endpoint from this trial. Our triple agonist mechanism page sets out what each receptor is known to do on its own.
Retatrutide
The compound discussed here, supplied as a research compound with a certificate of analysis matched to the lot.
The benefits that belong to other drugs
Many of the strongest incretin claims are real. They just were not earned by retatrutide. Cardiovascular, kidney and sleep-apnea findings come from the semaglutide and tirzepatide programs, which ran dedicated outcome trials over years.
Retatrutide has zero completed cardiovascular outcome trials. There is no approved label to carry an indication, because there is no approval at all — see retatrutide FDA approval status.
The other borrowed benefit is durability. SURMOUNT-4 tested what happens when tirzepatide is withdrawn after a run-in period.
Withdrawing tirzepatide led to substantial regain of lost weight, whereas continued treatment maintained and augmented initial weight reduction.
Aronne et al., JAMA, 2024 (SURMOUNT-4)That is a tirzepatide result. No equivalent randomized withdrawal study of retatrutide has been published. So the honest read is that any benefit measured in the 48-week trial is a benefit measured while the drug was being given.
The cost side of the ledger
A benefits page that omits the trade-offs is not a benefits page, it is an ad. In the Phase 2 trial the adverse events were class-typical and dose-dependent.
- Gastrointestinal events ran near 80% in the higher-dose arms — nausea, diarrhea, vomiting, constipation — mostly graded mild to moderate.
- Heart rate rose with dose, peaked around week 24, then came back down by week 48.
- Titration was part of the design. Participants stepped up over roughly 12 weeks rather than starting at the study dose.
Full detail is on retatrutide side effects, and what the trial administered is set out on the dosage guide as protocol, not instruction.
Is retatrutide better than tirzepatide?
No head-to-head trial has been published. Every comparison you have read, including the table below, is cross-trial.
| Compound | Trial | Mean body-weight reduction |
|---|---|---|
| Retatrutide 12 mg | Phase 2, 48 weeks, 338 adults | 24.2% |
| Tirzepatide | SURMOUNT-1, Phase 3 | 22.5% |
| Semaglutide | STEP-1, Phase 3 | 14.9% |
| Placebo (retatrutide trial) | Phase 2, 48 weeks | 2.1% |
Different populations, different durations, different trial sizes. SURMOUNT-1 was a Phase 3 program; the retatrutide figure comes from a dose-finding study one phase earlier.
What a real comparison looks like is SURPASS-2, where Frias and colleagues randomized participants with type 2 diabetes to tirzepatide or semaglutide in the same trial. That design is the only kind that settles a "better than" question, and retatrutide does not have one yet. More on the gap in retatrutide vs tirzepatide.
Retatrutide
Research-use-only material, sold by the vial with batch documentation. Check the certificate of analysis against the batch you receive.
What to know now
- The only benefit measured in a retatrutide trial is body-weight reduction, plus glycemic secondary endpoints, in 338 adults over 48 weeks.
- The headline figures are 24.2% at 12 mg against 2.1% on placebo, with 83% of that arm losing 15% or more.
- Claims about energy expenditure from the glucagon arm are mechanistic. No published human study splits the 24.2% between the three receptors.
- Cardiovascular, kidney and sleep-apnea benefits come from semaglutide and tirzepatide outcome trials. Retatrutide has none completed.
- Gastrointestinal events ran near 80% in higher-dose arms, and heart rate rose with dose before falling back by week 48.
- No head-to-head trial against tirzepatide exists, so every ranking you see is a cross-trial comparison.
What we're watching
The Phase 3 TRIUMPH readouts are the next real data point, and the question to ask of each one is whether it measures an outcome or a scale reading. Until a cardiovascular or kidney outcome trial reports, those benefits stay attached to other drugs.
Frequently asked questions
What is the main benefit of retatrutide?
Body-weight reduction, as measured in one published Phase 2 trial. Over 48 weeks in 338 adults, the 12 mg arm averaged a 24.2% drop and placebo averaged 2.1%. That is the claim with human data behind it.
Does retatrutide burn more fat than tirzepatide?
No trial has compared them directly. Retatrutide's 24.2% comes from a Phase 2 study and tirzepatide's 22.5% comes from Phase 3 SURMOUNT-1, in different populations. Cross-trial numbers cannot answer the question.
Does retatrutide help blood sugar?
The Phase 2 trial reported glycemic measures as secondary endpoints alongside weight. It was not a diabetes outcome trial. There is no approved indication for glucose control, because retatrutide has no approval anywhere.
Do the benefits last if the drug stops?
Unknown for retatrutide. No randomized withdrawal study of it has been published. SURMOUNT-4 tested this with tirzepatide and found that stopping led to substantial weight regain while continued treatment held the loss.
Is retatrutide approved for any of these benefits?
No. Retatrutide is investigational and in Phase 3 under Eli Lilly's TRIUMPH program. There is no label, no approved indication and no prescription route. Material sold online is sold as a research chemical.
References
- Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023). Triple–hormone-receptor agonist retatrutide for obesity — A phase 2 trial. New England Journal of Medicine, 389(6), 514–526. https://doi.org/10.1056/NEJMoa2301972
- Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., et al. (2022). Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038
- Aronne, L. J., Sattar, N., Horn, D. B., et al. (2024). Continued treatment with tirzepatide for maintenance of weight reduction in adults with obesity: The SURMOUNT-4 randomized clinical trial. JAMA, 331(1), 38–48. https://doi.org/10.1001/jama.2023.24945
- Frias, J. P., Davies, M. J., Rosenstock, J., et al. (2021). Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519
- Melson, E., Ashraf, U., Papamargaritis, D., & Davies, M. J. (2024). What is the pipeline for future medications for obesity? International Journal of Obesity, 49(3), 433–451. https://doi.org/10.1038/s41366-024-01473-y